Sangamo Therapeutics GAAP EPS of -$0.11 misses by $0.11, revenue of $0.6M misses by $33.8M

* Sangamo Therapeutics press release [https://seekingalpha.com/pr/20296724-sangamo-therapeutics-reports-recent-business-highlights-and-third-quarter-2025-financial] (SGMO [https://seekingalpha.com/symbol/SGMO]): Q3 GAAP EPS of -$0.11 misses by $0.11.
* Revenue of $0.6M (-98.8% Y/Y) misses by $33.8M.
*
On a GAAP basis, we continue to expect total operating expenses in the range of approximately $135 million to $155 million in 2025, which includes estimated non-cash stock-based compensation expense, and depreciation and amortization.

*
We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $7 million, and estimated depreciation and amortization of approximately $3 million, in the range of approximately $125 million to $145 million in 2025.

MORE ON SANGAMO THERAPEUTICS

* Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4811377-sangamo-therapeutics-inc-sgmo-q2-2025-earnings-call-transcript]
* Sangamo Therapeutics Q3 2025 Earnings Preview [https://seekingalpha.com/news/4515795-sangamo-therapeutics-q3-2025-earnings-preview]
* Sangamo Therapeutics falls on CFO retirement [https://seekingalpha.com/news/4494388-sangamo-therapeutics-falls-on-cfo-retirement]
* Seeking Alpha’s Quant Rating on Sangamo Therapeutics [https://seekingalpha.com/symbol/SGMO/ratings/quant-ratings]
* Historical earnings data for Sangamo Therapeutics [https://seekingalpha.com/symbol/SGMO/earnings]